Safety
liver injury, death, DLTs, TRAEs
DISEASE PROGRESSION, ADVERSE EVENT, ADRENAL INSUFFICIENCY
No DLTs were reported in the three patients enrolled in the DLT phase of each cohort. All patients experienced at least one TRAE (Summary of TRAEs.TRAE, treatment-related adverse event.TRAEs of any grade occurring in ≥20%.Serious AEs (SAEs) and treatment-related SAEs were reported in 42.4% of patients and 39.0% of patients, respectively. The most common SAEs were disease progression (6.8%), liver injury (6.8%), and adrenal insufficiency (5.1%). TRAEs leading to treatment discontinuation were reported in 11.9% of patients. TRAEs that led to death occurred in two patients (6.5%) in cohort A and one patient (3.6%) in cohort B; all three patients (5.1%) died due to disease progression.